Comparative proteomic analysis of membranous nephropathy biopsy tissues using quantitative proteomics

Experimental and Therapeutic Medicine

Volumn 9, Issue 3, 2015, Pages 805-810

  Sui, Weiguo ^a   Zhang, Ruohan ^a   Chen, Jiejing ^a   He, Huiyan ^a   Cui, Zhenzhen ^a,b   Ou, Minglin ^a   Guo, Li ^a   Cong, Shan ^a   Xue, Wen ^a   Dai, Yong ^a,c  

^a Central Laboratory of Guilin 181st Hospital   (China)

^b GUANGXI NORMAL UNIVERSITY   (China)

^c SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

Gene ontology analysis; Isobaric tags for relative and absolute quantification; Membranous nephropathy; Proteome

Indexed keywords

CD45 ANTIGEN; PROTEOME;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOWN REGULATION; FEMALE; GENE ONTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; KIDNEY BIOPSY; LIQUID CHROMATOGRAPHY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEMBRANOUS GLOMERULONEPHRITIS; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEINURIA; PROTEOMICS; TANDEM MASS SPECTROMETRY; UPREGULATION;

EID: 84922023752     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2197     Document Type: Article

References (19)

1. Papasotiriou M, Kalliakmani P, Huang L, et al: Does treatment with corticosteroids and cyclosporine reduce transglutaminase type 2 expression in the renal tissue of patients with membranous nephropathy? Nephron Clin Pract 121: c60-c67, 2012.
2. Beck LH Jr, Bonegio RG, Lambeau G, et al: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009.
3. Ngai HH, Sit WH, Jiang PP, et al: Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery. J Proteome Res 5: 3038-3047, 2006.
4. Thongboonkerd V: Biomarker discovery in glomerular diseases using urinary proteomics. Proteomics Clin Appl 2: 1413-1421, 2008.
5. Whittier WL and Korbet SM: Renal biopsy: update. Curr Opin Nephrol Hypertens 13: 661-665, 2004.
6. Veenstra TD: Global and targeted quantitative proteomics for biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 847: 3-11, 2007.
7. Duncan MW and Hunsucker SW: Proteomics as a tool for clinically relevant biomarker discovery and validation. Exp Biol Med (Maywood) 230: 808-817, 2005.
8. Sun C, Song C, Ma Z, et al: Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy. Proteome Sci 9: 22, 2011.
9. Sui W, Tang D, Zou G, et al: Differential proteomic analysis of renal tissue in lupus nephritis using iTRAQ reagent technology. Rheumatol Int 32: 3537-3543, 2012.
10. DeSouza L, Diehl G, Rodrigues MJ, et al: Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 4: 377-386, 2005.
11. Ralhan R, Desouza LV, Matta A, et al: Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 7:1162-1173, 2008.
12. Chen JS, Chen KT, Fan CW, et al: Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J 277: 3028-3038, 2010.
13. Irazabal MV, Eirin A, Lieske J, et al: Low-and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant 28: 137-146, 2013.
14. Wang L, Dai Y, Qi S, et al: Comparative proteome analysis of peripheral blood mononuclear cells in systemic lupus erythematosus with iTRAQ quantitative proteomics. Rheumatol Int 32: 585-593, 2012.
15. Hirayama K, Ebihara I, Yamamoto S, et al: Predominance of type-2 immune response in idiopathic membranous nephropathy. Cytoplasmic cytokine analysis. Nephron 91: 255-261, 2002.
16. Ronco P and Debiec H: Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 21: 564-569, 2010.
17. Werber HI, Emancipator SN, Tykocinski ML and Sedor JR: The interleukin 1 gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis. J Immunol 138: 3207-3212, 1987.
18. Hofstra JM, Deegens JK, Willems HL and Wetzels JF: Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy. Nephrol Dial Transplant 23: 2546-2551, 2008.
19. Branten AJ, du Buf-Vereijken PW, Klasen IS, et al: Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 16: 169-174, 2005.